Sign in

Private company

Gamida Cell Ltd.

Gamida Cell Ltd. is a biological products company.1

Last updated Oct 21, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersL31
  • Incorporated inIsrael2
  • Business address5 Nahum Hafzadi Street, Jerusalem, L3 954842
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-4094.1%Operating margin3
-3531.2%Net margin3
-$80.2MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue2¢$1.5M
  • Research and development31¢$24.3M
  • Selling, general and admin57¢$44.6M
  • Interest10¢$7.6M

Out of $1.8M in revenue.3 The company lost money this year.

Financial statements

Operating income45673-$73.0M in 2023+275% since 2017
-$100.0M-$75.0M-$50.0M-$25.0M02017: -$19.5M-$19.5M20172018: -$33.6M-$33.6M2018+73%2019: -$48.2M-$48.2M2019+43%2020: -$60.9M-$60.9M2020+26%2021: -$87.2M-$87.2M2021+43%2022: -$75.0M-$75.0M2022−14%2023: -$73.0M-$73.0M2023−3%
Net income45673-$63.0M in 2023+231% since 2017
-$100.0M-$75.0M-$50.0M-$25.0M02017: -$19.0M-$19.0M20172018: -$52.9M-$52.9M2018+178%2019: -$34.4M-$34.4M2019−35%2020: -$61.6M-$61.6M2020+79%2021: -$89.8M-$89.8M2021+46%2022: -$79.4M-$79.4M2022−12%2023: -$63.0M-$63.0M2023−21%
Fiscal year2017201820192020202120222023
Revenue$1.8M3
Cost of revenue$1.5M3
Research and development$1.1M6$50.2M7$42.7M3$24.3M3
Selling, general and admin$32.3M3$44.6M3
Operating expenses$359.0K7$75.0M3$73.4M3
Operating income-$19.5M4-$33.6M5-$48.2M5-$60.9M6-$87.2M7-$75.0M3-$73.0M3
Interest$5.7M3$7.6M3
Income before tax$89.8M6
Net income-$19.0M4-$52.9M5-$34.4M5-$61.6M6-$89.8M7-$79.4M3-$63.0M3
Earnings per share$27.564$10.535$1.175$1.665$1.243$0.573
Earnings per share (diluted)$27.564$10.535$1.695$1.665$1.243$0.573
Shares (weighted, basic)59.2M shares763.8M shares3110.0M shares3
Shares (weighted, diluted)59.2M shares763.8M shares3110.0M shares3

Compare Gamida Cell Ltd. with another company

Corporate structure

Gamida Cell Ltd. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Gamida Cell Ltd.

  • Gamida Cell Ltd. L3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Gamida Cell Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$46.1M3 Dec 31, 2023$48.8M3 Dec 31, 2022−5.5%
Accumulated depreciation$4.9M3 Dec 31, 2023$4.5M3 Dec 31, 2022+8.4%
Property and equipment, net$41.3M3 Dec 31, 2023$44.3M3 Dec 31, 2022−6.9%
Operating-lease assets (leased space)$3.2M3 Dec 31, 2023$7.0M3 Dec 31, 2022−54.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$46.6M3 Dec 31, 2023$64.7M3 Dec 31, 2022−28.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$1.9M3 Dec 31, 2023

Leadership

Who has led Gamida Cell Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Julian Adams2022

Chief financial officer

  1. Shai Lankry2022–2023
  2. Mary Theresa Coelho2023

Chief operating officer

  1. Michele Ilene Korfin2022–2024
2025
Board members and other officers (12)

Timeline

  1. May 24, 20248-K Ended a material agreement; Change to shareholders' rights; Change in control27
  2. May 10, 20248-K Other events28
  3. Apr 22, 20248-K Bankruptcy or receivership29
  4. Apr 11, 20248-K Other events30
  5. Apr 5, 20248-K Other events31
  6. Mar 29, 20248-K Listing notice or transfer; Other events32
  7. Mar 27, 20248-K Entered a material agreement; Results of operations; Debt or obligation accelerated33
  8. Mar 15, 20248-K Executive or director change34
  9. Jan 29, 20248-K Other events35
  10. Jan 8, 20248-K Regulation FD disclosure36
  11. Dec 18, 20238-K Executive or director change37
  12. Nov 24, 20238-K Listing notice or transfer38
  13. Jan 3, 2022New chief executive Julian Adams becomes CEO12

Calendar

When it reported results

  1. Mar 27, 2024Reported quarterly or annual results33
  2. Nov 14, 2023Reported quarterly or annual results39
  3. Aug 14, 2023Reported quarterly or annual results40
  4. May 15, 2023Reported quarterly or annual results41
  5. Mar 27, 2023Reported quarterly or annual results42
  6. Nov 14, 2022Reported quarterly or annual results43
  7. Aug 15, 2022Reported quarterly or annual results44
  8. May 10, 2022Reported quarterly or annual results45

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

202 filings to the SEC since October 2021: 3 annual reports, 7 quarterly reports, 47 major events, 66 insider forms, 29 large holders, 50 other. The latest 20:

  1. May 24, 202415-12G EDGAR
  2. May 24, 20248-K CURRENT REPORT EDGAR
  3. May 23, 202410-Q QUARTERLY REPORT EDGAR
  4. May 16, 2024NT 10-Q NOTIFICATION OF LATE FILING EDGAR
  5. May 13, 2024EFFECT EDGAR
  6. May 13, 2024EFFECT EDGAR
  7. May 13, 2024EFFECT EDGAR
  8. May 10, 20248-K/A AMENDMENT NO. 4 TO FORM 8-K EDGAR
  9. May 9, 2024S-8 POS POST-EFFECTIVE AMENDMENTS TO FORM S-8 EDGAR
  10. May 9, 2024S-8 POS POST-EFFECTIVE AMENDMENTS TO FORM S-8 EDGAR
  11. May 9, 2024S-8 POS POST-EFFECTIVE AMENDMENTS TO FORM S-8 EDGAR
  12. May 9, 2024POS AM POST-EFFECTIVE AMENDMENTS TO FORM S-3 EDGAR
  13. May 9, 2024POS AM POST-EFFECTIVE AMENDMENTS TO FORM S-3 EDGAR
  14. May 9, 2024POS AM POST-EFFECTIVE AMENDMENTS TO FORM S-3 EDGAR
  15. Apr 22, 20248-K CURRENT REPORT EDGAR
  16. Apr 11, 20248-K/A AMENDMENT NO. 3 TO FORM 8-K EDGAR
  17. Apr 5, 20248-K/A AMENDMENT NO. 2 TO FORM 8-K EDGAR
  18. Apr 1, 2024SC 13G/A EDGAR
  19. Mar 29, 20248-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
  20. Mar 27, 202410-K ANNUAL REPORT EDGAR

The 202 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 30, 2022WILLS STEPHEN TDirectorBuy9,677$1.55$15.0KForm 4
Sep 30, 2022Tomasello ShawnDirectorBuy9,677$1.55$15.0KForm 4
Sep 30, 2022Blum Robert IDirectorBuy50,000$1.55$77.5KForm 4
Sep 30, 2022Jenkins Abigail L.President and CEOBuy16,129$1.55$25.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Gamida Cell Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGamida Cell Ltd.1
  • CIK0001600847
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inIsrael1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address5 Nahum Hafzadi Street, Jerusalem, L3 954841
  • Phone972265956661
  • Shares outstanding154,013,109 as of May 16, 20249
  • Public float$216.7M as of Jun 30, 20233
  • On EDGAR sinceMar 6, 20141
  • Filings339 in all: 6-K (62), 8-K (43), 4 (41), SC 13G/A (19), 3 (17), SC 13G (15), SC 13D/A (14), CORRESP (13)1
    All 47 form types

    EFFECT (12), UPLOAD (9), 424B5 (8), 10-Q (7), 4/A (7), POS AM (5), 8-K/A (4), DEF 14A (4), PRE 14A (4), 10-K (3), 20-F (3), DEFA14A (3), DRS (3), DRS/A (3), F-3 (3), S-8 (3), S-8 POS (3), SC 13D (3), 424B4 (2), 424B7 (2), DEFR14A (2), DRSLTR (2), F-1 (2), F-1/A (2), S-3 (2), 15-12G (1), 20-F/A (1), 25-NSE (1), 3/A (1), 424B3 (1), 6-K/A (1), 8-A12B (1), 8-A12B/A (1), CERT (1), CT ORDER (1), F-1MEF (1), FWP (1), NT 10-Q (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2024
    Quarterly report (10-Q) May 23, 2024
    Proxy statement (DEF 14A) Sep 13, 2023
    Latest 8-K (8-K) May 24, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
    SEC EDGAROther events
  32. 32
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56